Corvus Pharmaceuticals Inc — Cash Flow (NASDAQ:CRVS) | MetaTrader

Open full chart

Financials

Overview Отчетность Statistics Dividends

Quarterly Annual

Cash from operating activities -34.78 M-36.72 M-27.02 M-23.93 M-25.42 M 12.94 M Cash from investing activities 44.77 M21.56 M23.28 M15.54 M27.48 M 24.76 M Cash from financing activities 1.31 M62.16 M62.16 M7.86 M49.03 M — Free cash flow -34.85 M-36.72 M-27.29 M-23.97 M-25.42 M 12.79 M

Новости

Corvus Pharmaceuticals, Inc. (CRVS) Discusses Phase 1 Clinical Trial Results of Soquelitinib in Atopic Dermatitis with Focus on Cohort 4 - Slideshow (NASDAQ:CRVS) 2026-01-27

Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why

Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should Know

Wall Street Analysts Think Corvus (CRVS) Could Surge 25.29%: Read This Before Placing a Bet

Intel, Oracle among market cap stock movers on Monday

Revolution Medicines, Erasca And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Ambitions Enterprise Mgmt (NASDAQ:AHMA), Argo Blockchain (NASDAQ:ARBK)

Apple, Microsoft, Meta To Report Results; Fed’s Interest Rate Decision In Focus

Corvus Pharmaceuticals привлекает $201,2 млн в расширенном публичном размещении

Corvus Pharmaceuticals raises $201.2 million in upsized public offering

Cantor Fitzgerald подтверждает рейтинг Corvus Pharmaceuticals

Cantor Fitzgerald reiterates Overweight rating on Corvus Pharmaceuticals stock

Jefferies повышает целевую цену акций Corvus Pharmaceuticals до $42